ZYUS Life Sciences Company Description

ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates for medical and adult recreational.

The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2a clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer.

It operates in Canada, the United States, Australia, and the European Union. ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Saskatoon, Canada.

ZYUS Life Sciences Corporation

Country	Canada
Founded	2018
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
CEO	Brent Zettl

Contact Details

Address: Unit 204 Saskatoon, SK S7N 4L8 Canada
Phone	888 651 9987
Website	zyus.com

Stock Details

Ticker Symbol	ZYUS
Exchange	TSX Venture Exchange
Fiscal Year	January - December
Reporting Currency	CAD
ISIN Number	CA9899601095
SIC Code	2834

Key Executives

Name	Position
Brent H. Zettl	President, Chief Executive Officer, Secretary and Director
John L. Knowles	Interim Chief Financial Officer and Director
Dr. Julie Stakiw FRCPC, M.D.	Chief Medical Officer
Scott William Livingstone	Vice President of Clinical Research
John William-Richard Eagle	Vice President of Finance and Accounting
Tim Miller	Director of Investor Relations and Capital Markets